# IONIS PHARMACEUTICALS INC

Summary updated: 2026-10-02T16:06:17.586548Z
Canonical: https://finbar.com/research/companies/ionis-pharmaceuticals-inc

## Overview

Ionis Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines targeting RNA, using antisense technology and other approaches to address serious diseases. Its focus areas include cardiometabolic, neurological and rare diseases. [1](https://ionis.com/science-and-innovation)

Its portfolio includes medicines it commercializes directly, including TRYNGOLZA and DAWNZERA, as well as partnered products such as SPINRAZA and WAINUA. [2](https://ionis.com/medicines) Ionis describes its mission as “to unlock better futures for people with serious diseases.” [3](https://ionis.com/about-us/corporate-responsibility/Ionis-Human-Rights-Commitment.pdf)

Ionis is headquartered in Carlsbad, California, with sites in Boston and Dublin, Ireland, and reports more than 1,500 employees. [4](https://ionis.com/media-center/corporate-factsheet.pdf) Revenue was $943.7 million in 2025; the company reported $514.0 million for the six months ended June 30, 2026. [5](https://app.finbar.com/go?id=T12409580)[6](https://app.finbar.com/go?id=T16531879) Ionis was founded in 1989 and completed its initial public offering in 1991. [7](https://ir.ionis.com/investor-resources/investor-faqs)
[1](https://ionis.com/science-and-innovation)[2](https://ionis.com/medicines)[3](https://ionis.com/about-us/corporate-responsibility/Ionis-Human-Rights-Commitment.pdf)[4](https://ionis.com/media-center/corporate-factsheet.pdf)[5](https://app.finbar.com/go?id=T12409580)[6](https://app.finbar.com/go?id=T16531879)[7](https://ir.ionis.com/investor-resources/investor-faqs)[1](https://ionis.com/science-and-innovation)[2](https://ionis.com/medicines)[3](https://ionis.com/about-us/corporate-responsibility/Ionis-Human-Rights-Commitment.pdf)[4](https://ionis.com/media-center/corporate-factsheet.pdf)[7](https://ir.ionis.com/investor-resources/investor-faqs)

## Products & services

Ionis’s marketed portfolio includes seven medicines. TRYNGOLZA (olezarsen) is a once-monthly, self-administered ligand-conjugated antisense medicine. In the U.S., it is approved as an adjunct to diet to reduce triglycerides and acute-pancreatitis risk in adults with severe hypertriglyceridemia, and to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS); it is also approved in the EU, Canada and UK for genetically confirmed adult FCS. [8](https://app.finbar.com/go?id=P144467005)[9](https://app.finbar.com/go?id=P144466802) DAWNZERA (donidalorsen) is an RNA-targeted medicine delivered by subcutaneous autoinjector every four or eight weeks for routine prevention of hereditary angioedema attacks in adults and children aged 12 and older in the U.S., EU and UK. [10](https://app.finbar.com/go?id=P144467008)

WAINUA (eplontersen), also called WAINZUA in Europe, is a once-monthly, self-administered subcutaneous medicine for adults with hereditary transthyretin-mediated amyloidosis polyneuropathy; U.S. commercialization is shared with AstraZeneca, which commercializes it outside the U.S. [11](https://app.finbar.com/go?id=P144467010)[12](https://app.finbar.com/go?id=P144467002) SPINRAZA (nusinersen) is an antisense medicine for spinal muscular atrophy, including a higher-dose version approved in the U.S. and EU; Biogen commercializes it worldwide. [13](https://app.finbar.com/go?id=P144467009) QALSODY (tofersen) is an antisense medicine for adults with SOD1-ALS and is commercialized worldwide by Biogen. [14](https://app.finbar.com/go?id=P144467011)

TEGSEDI (inotersen) is a once-weekly, self-administered subcutaneous medicine for hereditary transthyretin-mediated amyloidosis polyneuropathy, approved in Europe and Brazil. [15](https://app.finbar.com/go?id=P144467012) WAYLIVRA (volanesorsen) is a once-weekly, self-administered subcutaneous medicine approved in Europe and Brazil as an adjunct to diet for adults with genetically confirmed FCS at high risk of pancreatitis; in Brazil it is also commercialized for familial partial lipodystrophy. [16](https://app.finbar.com/go?id=P144467013) The company also has investigational candidates, including zilganersen for Alexander disease, pelacarsen for cardiovascular disease associated with elevated Lp(a), sefaxersen for IgA nephropathy, and ulefnersen for FUS-ALS. [17](https://app.finbar.com/go?id=P144467015)[18](https://app.finbar.com/go?id=P144467022)[19](https://app.finbar.com/go?id=P144467025)[20](https://app.finbar.com/go?id=P144467027)
[8](https://app.finbar.com/go?id=P144467005)[9](https://app.finbar.com/go?id=P144466802)[10](https://app.finbar.com/go?id=P144467008)[11](https://app.finbar.com/go?id=P144467010)[12](https://app.finbar.com/go?id=P144467002)[13](https://app.finbar.com/go?id=P144467009)[14](https://app.finbar.com/go?id=P144467011)[15](https://app.finbar.com/go?id=P144467012)[16](https://app.finbar.com/go?id=P144467013)[17](https://app.finbar.com/go?id=P144467015)[18](https://app.finbar.com/go?id=P144467022)[19](https://app.finbar.com/go?id=P144467025)[20](https://app.finbar.com/go?id=P144467027)

## Geographic presence

Ionis Pharmaceuticals’ principal operating base is in Carlsbad, California. Its facilities there include laboratory and office space, manufacturing and manufacturing-support facilities, and a warehouse. The company also lists an office in Boston, Massachusetts, and an office in Dublin, Ireland. Its headquarters address is 2855 Gazelle Court, Carlsbad, California. [21](https://app.finbar.com/go?id=T6725282)[22](https://app.finbar.com/go?id=P20309174)[23](https://ionis.com/contact-us)

Its commercial reach spans the United States and international markets: company medicines have approvals or sales in the United States, the European Union, China, Brazil and other countries, with some products commercialized by partners in global markets. Ionis’s disclosures do not provide a country- or region-level revenue breakdown; the company reports as one operating segment on a consolidated basis. [24](https://app.finbar.com/go?id=T4307500)[25](https://app.finbar.com/go?id=P47628842)[26](https://app.finbar.com/go?id=P108838256)[27](https://app.finbar.com/go?id=P80058423)[28](https://app.finbar.com/go?id=P96250645)[29](https://app.finbar.com/go?id=P104932808)
[21](https://app.finbar.com/go?id=T6725282)[22](https://app.finbar.com/go?id=P20309174)[24](https://app.finbar.com/go?id=T4307500)[25](https://app.finbar.com/go?id=P47628842)[26](https://app.finbar.com/go?id=P108838256)[27](https://app.finbar.com/go?id=P80058423)[28](https://app.finbar.com/go?id=P96250645)[29](https://app.finbar.com/go?id=P104932808)[23](https://ionis.com/contact-us)

## Business segments

Ionis Pharmaceuticals reports one operating and reportable segment, “Ionis operations,” encompassing the company’s research, development, and commercialization of RNA-targeted medicines. Accordingly, this segment represents 100% of the company’s reported segment activity; Ionis does not report separate accounting segments by product, therapeutic area, or partnered versus wholly owned operations. [29](https://app.finbar.com/go?id=P104932808)[28](https://app.finbar.com/go?id=P96250645)

The company reviews performance and allocates resources on a consolidated basis. Its revenue disclosures by commercial activity and research-and-development agreements are revenue categories, not separately reported segments, so they do not represent segment contribution percentages. [29](https://app.finbar.com/go?id=P104932808)
[29](https://app.finbar.com/go?id=P104932808)[28](https://app.finbar.com/go?id=P96250645)

## Company history

Ionis Pharmaceuticals was founded in 1989 as Isis Pharmaceuticals, with Stanley T. Crooke among its founders, to develop antisense medicines. Its early history included Vitravene, which reached the market in 1998 as the first antisense drug, and the 2013 U.S. approval of KYNAMRO, an antisense medicine delivered systemically. [30](https://app.finbar.com/go?id=P55472490)[31](https://ionis.com/about-us/the-ionis-story)[32](https://ir.ionis.com/news-releases/news-release-details/isis-reports-financial-results-and-highlights-2013)

In 2015, the company changed its name from Isis Pharmaceuticals to Ionis Pharmaceuticals and entered a significant antisense-drug collaboration with AstraZeneca. A development collaboration with Biogen led to FDA approval of SPINRAZA in 2016. Ionis took Akcea Therapeutics public in 2017 and acquired its remaining shares in 2020; that year, Crooke transitioned from CEO to executive chairman and Brett P. Monia became CEO. [33](https://app.finbar.com/go?id=P33297485)[34](https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-isis-pharmaceuticals-antisense-drugs-cardiovascular-metabolic-renal-diseases-03082015.html)[35](https://app.finbar.com/go?id=P112326584)[36](https://ir.ionis.com/news-releases/news-release-details/akcea-therapeutics-announces-pricing-initial-public-offering)[37](https://www.prnewswire.com/news-releases/ionis-pharmaceuticals-completes-acquisition-of-akcea-therapeutics-301150205.html)[38](https://www.sec.gov/Archives/edgar/data/874015/000114036118045553/ex99_1.htm)

Further approvals marked the expansion of its medicine portfolio: TEGSEDI in 2018 and WAYLIVRA in the EU in 2019, followed by QALSODY and WAINUA in the United States in 2023. In 2024 and 2025, the FDA approved TRYNGOLZA and DAWNZERA, respectively, medicines Ionis said it was commercializing independently in the United States. [39](https://ir.ionis.com/news-releases/news-release-details/ionis-exceeds-2018-financial-guidance)[40](https://ir.ionis.com/news-releases/news-release-details/akcea-and-ionis-report-top-line-results-broaden-study-waylivrar)[41](https://ir.ionis.com/news-releases/news-release-details/fda-approves-qalsodytm-tofersen-first-treatment-targeting)[42](https://ir.ionis.com/news-releases/news-release-details/wainuatm-eplontersen-granted-regulatory-approval-us-treatment/)[43](https://ir.ionis.com/news-releases/news-release-details/tryngolzatm-olezarsen-approved-us-first-ever-treatment-adults)[44](https://app.finbar.com/go?id=P96904619)
[30](https://app.finbar.com/go?id=P55472490)[33](https://app.finbar.com/go?id=P33297485)[35](https://app.finbar.com/go?id=P112326584)[44](https://app.finbar.com/go?id=P96904619)

## Sources

1. [ionis.com](https://ionis.com/science-and-innovation)
2. [ionis.com](https://ionis.com/medicines)
3. [ionis.com](https://ionis.com/about-us/corporate-responsibility/Ionis-Human-Rights-Commitment.pdf)
4. [ionis.com](https://ionis.com/media-center/corporate-factsheet.pdf)
5. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T12409580)
6. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16531879)
7. [ir.ionis.com](https://ir.ionis.com/investor-resources/investor-faqs)
8. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467005)
9. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144466802)
10. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467008)
11. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467010)
12. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467002)
13. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467009)
14. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467011)
15. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467012)
16. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467013)
17. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467015)
18. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467022)
19. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467025)
20. [IONIS PHARMACEUTICALS INC — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144467027)
21. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T6725282)
22. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P20309174)
23. [ionis.com](https://ionis.com/contact-us)
24. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=T4307500)
25. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P47628842)
26. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P108838256)
27. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P80058423)
28. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P96250645)
29. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P104932808)
30. [IONIS PHARMACEUTICALS INC — Full financial report (2015 Y)](https://app.finbar.com/go?id=P55472490)
31. [ionis.com](https://ionis.com/about-us/the-ionis-story)
32. [ir.ionis.com](https://ir.ionis.com/news-releases/news-release-details/isis-reports-financial-results-and-highlights-2013)
33. [IONIS PHARMACEUTICALS INC — Full financial report (2015 Y)](https://app.finbar.com/go?id=P33297485)
34. [www.astrazeneca.com](https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-isis-pharmaceuticals-antisense-drugs-cardiovascular-metabolic-renal-diseases-03082015.html)
35. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P112326584)
36. [ir.ionis.com](https://ir.ionis.com/news-releases/news-release-details/akcea-therapeutics-announces-pricing-initial-public-offering)
37. [www.prnewswire.com](https://www.prnewswire.com/news-releases/ionis-pharmaceuticals-completes-acquisition-of-akcea-therapeutics-301150205.html)
38. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/874015/000114036118045553/ex99_1.htm)
39. [ir.ionis.com](https://ir.ionis.com/news-releases/news-release-details/ionis-exceeds-2018-financial-guidance)
40. [ir.ionis.com](https://ir.ionis.com/news-releases/news-release-details/akcea-and-ionis-report-top-line-results-broaden-study-waylivrar)
41. [ir.ionis.com](https://ir.ionis.com/news-releases/news-release-details/fda-approves-qalsodytm-tofersen-first-treatment-targeting)
42. [ir.ionis.com](https://ir.ionis.com/news-releases/news-release-details/wainuatm-eplontersen-granted-regulatory-approval-us-treatment/)
43. [ir.ionis.com](https://ir.ionis.com/news-releases/news-release-details/tryngolzatm-olezarsen-approved-us-first-ever-treatment-adults)
44. [IONIS PHARMACEUTICALS INC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P96904619)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.